Taysha Gene Therapies (NASDAQ:TSHA) Receives "Buy" Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $8.00 price target on the stock, up from their previous price target of $6.00.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. JMP Securities lifted their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Chardan Capital lifted their price target on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $7.57.

Taysha Gene Therapies Trading Up 0.4%

NASDAQ TSHA traded up $0.01 during trading on Monday, reaching $2.79. 4,276,991 shares of the stock traded hands, compared to its average volume of 3,012,049. The firm has a market cap of $598.91 million, a price-to-earnings ratio of 4.43 and a beta of 0.90. The stock's 50-day moving average price is $1.98 and its 200 day moving average price is $1.92. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The firm had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter in the previous year, the company earned ($0.10) earnings per share. Analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the transaction, the insider now directly owns 2,841,704 shares in the company, valued at $7,814,686. This trade represents a 35.86% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.70% of the company's stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently made changes to their positions in TSHA. Ground Swell Capital LLC bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $25,000. Cibc World Markets Corp bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $28,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $31,000. Hsbc Holdings PLC lifted its position in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after purchasing an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $39,000. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.